INZY: Inozyme Pharma Expected earnings per share growth for next year

Inozyme Pharma, Inc. (INZY) develops advanced enzyme therapies to combat tissue mineralization pathologies. The business is currently spending capital on research without stable cash inflows. The projected net profit trend indicates that the current level is around 39.90. In the long term, patents for treating rare genetic calcification diseases will allow the company to monetize its developments through drug exclusivity.

Inozyme Pharma Inc. (INZY): Net earnings per share change forecast for next year from 07/04/2022 to 07/12/2025

Analytical breakdowns and data insights for company Inozyme (INZY)

- share price and consensus valuation forecast:

Stock Price Inozyme Pharma|INZY - Broker Consensus Forecast

- market capitalization information:

Market Valuation Inozyme|INZY - Value Adjusted for Debt and Cash

- book capitalization information:

Net Assets per Single Share Inozyme Pharma|INZY - Net Asset Value|Market Capitalization to Book Value Ratio inozyme.com|INZY - Aggregate Asset Value

- company total debt and liquidity indicators:

- net income and valuation ratios data:

INZY - Net Financial Result|Expected Profit Inozyme Pharma, Inc.|INZY - Price to Earnings Multiple|Future Price to Earnings Inozyme Pharma Inc.|INZY - Price to Earnings Adjusted for Growth Rate|Enterprise Value to EBITDA Ratio Inozyme Pharma, Inc.|INZY - Profit before deduction of interest, taxes, depreciation and amortization|Net earnings per share for the last 12 months Inozyme Pharma|INZY - Net earnings per one share for the last twelve months|Year-over-year earnings per share growth for the last twelve months inozyme.com|INZY - Net earnings per share growth this year|Earnings growth forecast for next year Inozyme Pharma, Inc.

- sales revenue and business income indicators:

INZY - Company Total Revenue|Company Future Sales Volume inozyme.com|INZY - Market Capitalization-to-Revenue Ratio|Price-to-Projected Revenue Ratio Inozyme Pharma, Inc.|INZY - Trailing Twelve Months Sales Growth

Fundamental company valuation:INZY, Inozyme Pharma Inc.

Finished products of Inozyme Pharma Inc.

Amid intense competition in rare disease therapy, the success of Inozyme Pharma, Inc. (INZY) depends on clinical trial outcomes and market positioning. This metric aggregates revised analyst earnings forecasts for the coming year, reflecting market expectations for drug commercialization. Positive momentum in the growth assessment of next year's EPS confirms the business's fundamental resilience, whereas sharp declines signal critical risks.

Analysis of competing companies